缬沙坦降低肝硬化门静脉高压的疗效观察  

Different doses of valsartan in the treatment of portal hypertension in patients with hepatic cirrhosis

作　　者：谭鹤龙 刘兵 周胜玉 周秀琴 印德民 黄玉凯[3] 

机构地区：[1]上海市青浦区中医医院消化内科,上海201700 [2]上海市青浦区中医医院超声诊断科,上海201700 [3]安徽省淮南市第一人民医院消化内科,安徽淮南232052

出　　处：《同济大学学报（医学版）》2010年第5期99-101,共3页Journal of Tongji University(Medical Science)

摘　　要：目的探讨两种不同剂量缬沙坦降低肝硬化门静脉高压的疗效。方法将肝硬化门脉高压患者40例随机分为两组,每组20例。一组口服缬沙坦40m g/d,另一组口服缬沙坦80m g/d,疗程2周。治疗前后应用彩色多谱勒超声仪分别测量门、脾静脉内径和最大血流速度。结果治疗后两组患者门、脾静脉的内径下降,血流速度增快,用药前后比较,差异有统计学意义(P<0.01)。而治疗后两组上述指标比较,差异无统计学意义(P>0.05)。结论两种不同剂量缬沙坦降低肝硬化门静脉高压的疗效相同。Objective To explore effects of different doses of valsartan on alleviation of portal hypertension in patients with cirrhosis.Methods 40 liver cirrhosis patients with portal hypertension were randomized to be either treated with valsartan（40mg/d） or with（80mg/d）.The effectiveness of the medicine was evaluated by measuring diameter of portal vien（DPV）,velocity of the blood flow in the portal vien（VPV）,diameter of splenic vien（DSV） and velocity of the blood flood of splenic vein（VSV） with Doppler before and after 2-weeks＇ treatment.Results The diameters of portal and splenic veins were significantly decreased.whereas the velocities of the blood flow in portal and splenic veins were significantly increased following either low or high dose of valsartan treatment.However there was no statistically significant difference between low dose or high dose treatment.Conclusion Valsartan（40mg/d） is as effective as valsartan（80mg/d） in reducing portal pressure in patient with portal hypertension resulted from liver cirrhosis.

关 键 词：缬沙坦 肝硬化 彩色多谱勒 

分 类 号：R575.2[医药卫生—消化系统]